The spectre of teratogenesis has been hanging over young women with epilepsy ever since the association of fetal malformations with antiepileptic drug (AED) exposure was first mooted by Roy Meadow in a letter to The Lancet in 1968.¹ There followed a flood of retrospective reports and small prospective studies suggesting that perhaps all of the established drugs could be implicated in this problem. The global licensing of nine new antiepileptic drugs over the past 15 years has added to the confusion. Those agents that did not appear to be teratogenic in rodents have been touted by enthusiasts as “possibly” …